Overview

HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES To investigate: - the mechanism of Valproic Acid (VPA)-induced apoptosis in B-CLL - the ability of VPA in combination with standard chemotherapy or new antitumor agents to induce a synergistic antitumor effect in chronic lymphocytic leukemia (CLL) cells - the clinical efficacy of VPA in previously treated CLL patients. This will be an example of a translational research study where the results of our laboratory studies will be applied to a clinical trial in the CLL clinic at CancerCare Manitoba.
Phase:
Phase 2
Details
Lead Sponsor:
CancerCare Manitoba
Collaborator:
The Leukemia and Lymphoma Society
Treatments:
Fludarabine
Fludarabine phosphate
Histone Deacetylase Inhibitors
Valproic Acid